Assenagon Asset Management S.A. Decreases Stock Position in Henry Schein, Inc. $HSIC

Assenagon Asset Management S.A. decreased its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 52.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,480 shares of the company’s stock after selling 23,586 shares during the period. Assenagon Asset Management S.A.’s holdings in Henry Schein were worth $1,426,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein in the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein in the 2nd quarter worth $27,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein in the 2nd quarter worth $43,000. Steph & Co. purchased a new stake in shares of Henry Schein during the 2nd quarter worth $44,000. Finally, CX Institutional raised its stake in shares of Henry Schein by 107.3% during the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after acquiring an additional 337 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research report on Monday. Evercore ISI boosted their price target on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Wells Fargo & Company increased their price target on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Finally, Barclays assumed coverage on Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $76.92.

Henry Schein Stock Down 0.4%

Shares of HSIC opened at $76.21 on Thursday. The company’s 50-day simple moving average is $71.25 and its 200-day simple moving average is $69.90. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The stock has a market capitalization of $8.97 billion, a PE ratio of 24.12, a P/E/G ratio of 2.35 and a beta of 0.89.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.